Regulation - Regulation, ALK Abello

Filter

Current filters:

RegulationALK Abello

Popular Filters

FDA approves Merck’s Ragwitek for short ragweed pollen allergies

18-04-2014

The US Food and Drug Administration has approved US pharma giant Merck & Co’s Biological License Application…

ALK AbelloImmunologicalsMerck & CoNorth AmericaPharmaceuticalRagwitekRegulationUSA

ALK and Merck Co’s grass allergy tablet finally reaches FDA committee

ALK and Merck Co’s grass allergy tablet finally reaches FDA committee

10-12-2013

The US Food and Drug Administration Allergenic Products Advisory Committee will review US pharma giant…

ALK AbelloImmunologicalsMerck & CoPharmaceuticalRegulationUSA

ALK’s allergy tablet falls victim to US government shutdown

ALK’s allergy tablet falls victim to US government shutdown

08-10-2013

ALK Abello is the first pharma casualty of the US government shutdown.

ALK AbelloImmunologicalsMerk & CoNorth AmericaPharmaceuticalRegulation

Positive Ph III findings on ALK's new house dust mite allergy immunotherapy; EU filing expected in 2014

20-06-2013

Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced positive outcome of the first of…

ALK AbelloImmunologicalsPharmaceuticalRegulationResearchRespiratory and Pulmonary

US FDA accepts Merck & Co's BLA for Timothy grass pollen allergy product

27-03-2013

US pharma giant Merck & Co (NYSE: MRK) says that its Biologics License Application for the investigational…

ALK AbelloGrazaxImmunologicalsMerck & CoPharmaceuticalRegulationRespiratory and Pulmonary

Merck & Co submits ragweed AIT BLA to the FDA

11-03-2013

US pharma giant Merck & Co (NYSE: MRK) has submitted a Biologics License Application (BLA) to the US…

ALK AbelloFinancialImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

FDA calls for more data on Merck combo drug; Good results with allergy drug

06-03-2012

The US Food and Drug Administration (FDA) has issued a Complete Response Letter to drug giant Merck &…

ALK AbelloatorvastatinCardio-vascularezetimibeImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulationResearch

UK NICE says yes to Lilly’s Bydureon and ALK-Abello’s Pharmalgen

22-02-2012

The UK’s health care guidance body the National Institute for Health and Clinical Excellence (NICE),…

ALK AbelloBydureonDiabetesEli LillyEuropePharmaceuticalPharmalgenPricingRegulationRespiratory and Pulmonary

Back to top